InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,187.70
(
0.13%
)
US TECH 100
17,618.80
(
0.05%
)
Dow Jones
38,884.26
(
0.08%
)
Brent Oil
82.55
(
-0.39%
)
Bitcoin
62,585.77
(
0.40%
)
Post# of 29302
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

biocqr

Send PM Follow Ignore
Followers 49
Posts 3515
Boards Moderated 0
Alias Born 08/24/2005

biocqr

Member Level

Re: biotech jim post# 17176

Thursday, 09/20/2018 5:15:27 PM

Thursday, September 20, 2018 5:15:27 PM

Post# of 29302

3. Due to reactive metabolite species for VKTX, can company comment on the metabolite being a CYP P450 3A4 covalent inhibitor? Data for similar reactive species in literature shows this could be a major problem for concomitant drugs to be source for drug-drug interaction. (Note that 3A4 is the source for the reactive metabolite.)



Jim, since VK2809 is a prodrug wouldn't that help mitigate drug/drug interactions?

seemed ok pre-clinic...

MB07811/VK2809 in combination with atorvastatin in rabbits, dogs and monkeys.

Before advancing to a NASH phase 3, wouldn't VK2809 be required to go through a phase 2 statin/combo trial and a NASH phase 2 with biopsies?
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up